Loading company…
New York-based developer of gene therapies for rare neurological diseases, led by its NGN-401 candidate for Rett syndrome.
Founded in 2018 and headquartered in New York, US, Neurogene Inc. develops genetic medicines for rare neurological diseases. Its CEO is Rachel McMinn. The company completed 4 funding deals, most recently a PIPE round of USD 200.00 mn on November 4, 2024, with investors including Casdin Capital and EcoR1 Capital. Its lead candidate, NGN-401, uses the proprietary EXACT technology to regulate transgene expression for Rett syndrome.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in